Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines

被引：1
|
作者：
Packer, L. [1 ]
Geng, X. [1 ]
Bonazzi, V. [1 ]
Mahon, C. [1 ]
Ju, R. [1 ]
Stephenson, S. [1 ]
Pollock, P. [1 ]
机构：
[1] Queensland Univ Technol, Sch Biomed Sci, Inst Hlth & Innovat, Translat Res Inst, Brisbane, Qld, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 61卷
关键词：
D O I：
10.1016/S0959-8049(16)61523-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [41] Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
    Alessio Fiascarelli
    Giuseppe Merlino
    Stefania Capano
    Simone Talucci
    Diego Bisignano
    Alessandro Bressan
    Daniela Bellarosa
    Corrado Carrisi
    Alessandro Paoli
    Mario Bigioni
    Patrizia Tunici
    Clelia Irrissuto
    Massimiliano Salerno
    Joaquin Arribas
    Elisa de Stanchina
    Maurizio Scaltriti
    Monica Binaschi
    Breast Cancer Research and Treatment, 2023, 199 : 13 - 23
  • [42] Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2+breast cancer
    Fiascarelli, Alessio
    Merlino, Giuseppe
    Capano, Stefania
    Talucci, Simone
    Bisignano, Diego
    Bressan, Alessandro
    Bellarosa, Daniela
    Carrisi, Corrado
    Paoli, Alessandro
    Bigioni, Mario
    Tunici, Patrizia
    Irrissuto, Clelia
    Salerno, Massimiliano
    Arribas, Joaquin
    de Stanchina, Elisa
    Scaltriti, Maurizio
    Binaschi, Monica
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 13 - 23
  • [43] MEK and PI3K signaling cooperate through mTORC1/2 to promote PIK3CA mutant melanoma cell proliferation
    Silva, Jillian M.
    Deuker, Marian M.
    Baguley, Bruce C.
    McMahon, Martin
    CANCER RESEARCH, 2016, 76
  • [44] Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR plus Breast Cancer
    Sreekumar, Sreeja
    Painsec, Pierre
    Klein, Davis
    Gonzalez, Dalia
    Sourd, Laura
    Montaudon, Elodie
    Smeal, Tod
    Marangoni, Elisabetta
    Ridinger, Maya
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216
    Walls, Marlena
    Mehta, Pramod P.
    Baxi, Sangita M.
    Liu, Kevin
    Li, Chunze
    Smeal, Tod
    Yin, Min-Jean
    CANCER RESEARCH, 2011, 71
  • [46] Combination of the Dual Pan-PI3K/PIM Inhibitor Ibl-202 with the BCL-2 Inhibitor Venetoclax Enhances Apoptotic Priming and Is an Effective Targeted Treatment Approach in Mantle Cell Lymphoma
    Gaiderov, Anton
    Burkhard-Meier, Anton
    Hildebrand, Johannes Adrian
    Koestler, Maximilian Alexander Maurice
    Roue, Gael
    Dreyling, Martin
    Silkenstedt, Elisabeth Theresa
    BLOOD, 2024, 144 : 5825 - 5826
  • [47] A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, In Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours
    Banerjee, S.
    Baird, R.
    Basu, B.
    Shah, K.
    Tunariu, N.
    Garcia, V. Moreno
    Corral, J.
    Mazina, K.
    Levy, G.
    de Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S159 - S159
  • [48] Activation of WNT/b-catenin signaling results in resistance to PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colorectal cancer cells
    Park, Ye-Lim
    Kim, Hwang-Phill
    Cheon, Seul-Ki
    Kang, Jun-Kyu
    Lim, Yoojoo
    Song, Sang-Hyun
    Han, Sae-Won
    Kim, Tae-you
    CANCER RESEARCH, 2017, 77
  • [49] MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation
    Henry, C.
    Geslin, C.
    Blanchet, A. M.
    Nicolazzi, C.
    Garcia, G.
    Vincent, L.
    Blanc, V.
    Tabah-Fisch, I.
    Chiron, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 99 - 99
  • [50] PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells
    Thibault, Benoit
    Thole, Adrien
    D'Angelo, Romina
    Basset, Celine
    Guillermet-Guibert, Julie
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345